LYSOGENE Releases the Results From June 25, 2021 Ordinary Annual and Extraordinary General Meeting
25 Giugno 2021 - 6:00PM
Business Wire
- Shareholders approved all proposed resolutions
Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS), a phase 3 gene
therapy platform Company targeting central nervous system (CNS)
diseases, held its ordinary annual and extraordinary general
meeting of shareholders on June 25, 2021, which was chaired by
Karen Aiach, Chairman of the Board of directors and chief executive
officer.
With a quorum of 49.98 %, the shareholders have adopted all the
resolutions approved by the Board of Directors, including the
financial statements for the 2020 financial year, the compensation
policy applicable to the Chairman and Chief Executive Officer and
the directors, as well as delegations granted to the Board of
Directors related to financial transactions.
Details on the vote results will be available on the company’s
website.
About Lysogene Lysogene is a gene therapy Company focused
on the treatment of orphan diseases of the central nervous system
(CNS). The Company has built a unique capability to enable a
delivery of gene therapies to the CNS to treat lysosomal diseases
and other genetic disorders of the CNS. A phase 2/3 clinical trial
in MPS IIIA in partnership with Sarepta Therapeutics, Inc. is
ongoing. An adaptive clinical trial in GM1 gangliosidosis is
ongoing. In accordance with the agreements signed between Lysogene
and Sarepta Therapeutics, Inc., Sarepta Therapeutics, Inc. will
hold exclusive commercial rights to LYS-SAF302 in the United States
and markets outside Europe; and Lysogene will maintain commercial
exclusivity of LYS-SAF302 in Europe. Lysogene is also collaborating
with an academic partner to define the strategy of development for
the treatment of Fragile X syndrome, a genetic disease related to
autism. www.lysogene.com.
Forward Looking Statement This press release may contain
certain forward-looking statements, especially on the Company’s
progress of its clinical trials and cash runway. Although the
Company believes its expectations are based on reasonable
assumptions, all statements other than statements of historical
fact included in this press release about future events are subject
to (i) change without notice, (ii) factors beyond the Company’s
control, (iii) clinical trial results, (iv) increased manufacturing
costs and (v) potential claims on its products. These statements
may include, without limitation, any statements preceded by,
followed by or including words such as “target,” “believe,”
“expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,”
“objective”, “project,” “will,” “can have,” “likely,” “should,”
“would,” “could” and other words and terms of similar meaning or
the negative thereof. Forward-looking statements are subject to
inherent risks and uncertainties beyond the Company’s control that
could cause the Company’s actual results, performance or
achievements to be materially different from the expected results,
performance or achievements expressed or implied by such
forward-looking statements. A further list and description of these
risks, uncertainties and other risks can be found in the Company’s
regulatory filings with the French Autorité des Marchés Financiers,
including in the 2020 universal registration document, registered
with the French Markets Authorities on April 12, 2021, under number
D.21-0296, and future filings and reports by the Company.
Furthermore, these forward-looking statements are only as of the
date of this press release. Readers are cautioned not to place
undue reliance on these forward-looking statements. Except as
required by law, the Company assumes no obligation to update these
forward-looking statements publicly, or to update the reasons
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future. If the Company updates one or more
forward-looking statements, no inference should be drawn that it
will or will not make additional updates with respect to those or
other forward-looking statements.
This press release has been prepared in both French and English.
In the event of any differences between the two texts, the French
language version shall supersede.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210625005167/en/
Stéphane Durant des Aulnois Chief Financial Officer
stephane.durant-des-aulnois@lysogene.com + 33 1 41 43 03 99